Association Between Apelin and Atrial Fibrillation in Patients With High Risk of Ischemic Stroke

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985807%3A_____%2F21%3A00546972" target="_blank" >RIV/67985807:_____/21:00546972 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.3389/fcvm.2021.742601" target="_blank" >http://dx.doi.org/10.3389/fcvm.2021.742601</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fcvm.2021.742601" target="_blank" >10.3389/fcvm.2021.742601</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Association Between Apelin and Atrial Fibrillation in Patients With High Risk of Ischemic Stroke

Popis výsledku v původním jazyce

BACKGROUND: Atrial fibrillation (AF) is associated with high risk of stroke preventable by timely initiation of anticoagulation. Currently available screening tools based on ECG are not optimal due to inconvenience and high costs. Aim of this study was to study the diagnostic value of apelin for AF in patients with high risk of stroke. METHODS: We designed a multicenter, matched-cohort study. The population consisted of three study groups: a healthy control group (34 patients) and two matched groups of 60 patients with high risk of stroke (AF and non-AF group). Apelin levels were examined from peripheral blood. RESULTS: Apelin was significantly lower in AF group compared to non-AF group (0.694 ± 0.148 vs. 0.975 ± 0.458 ng/ml, p = 0.001) and control group (0.982 ± 0.060 ng/ml, p < 0.001), respectively. Receiver operating characteristic (ROC) analysis of apelin as a predictor of AF scored area under the curve (AUC) of 0.658. Apelin's concentration of 0.969 [ng/ml] had sensitivity = 0.966 and specificity = 0.467. Logistic regression based on manual feature selection showed that only apelin and NT-proBNP were independent predictors of AF. Logistic regression based on selection from bivariate analysis showed that only apelin was an independent predictor of AF. A logistic regression model using repeated stratified K-Fold cross-validation strategy scored an AUC of 0.725 ± 0.131. CONCLUSIONS: Our results suggest that apelin might be used to rule out AF in patients with high risk of stroke.

Název v anglickém jazyce

Association Between Apelin and Atrial Fibrillation in Patients With High Risk of Ischemic Stroke

Popis výsledku anglicky

BACKGROUND: Atrial fibrillation (AF) is associated with high risk of stroke preventable by timely initiation of anticoagulation. Currently available screening tools based on ECG are not optimal due to inconvenience and high costs. Aim of this study was to study the diagnostic value of apelin for AF in patients with high risk of stroke. METHODS: We designed a multicenter, matched-cohort study. The population consisted of three study groups: a healthy control group (34 patients) and two matched groups of 60 patients with high risk of stroke (AF and non-AF group). Apelin levels were examined from peripheral blood. RESULTS: Apelin was significantly lower in AF group compared to non-AF group (0.694 ± 0.148 vs. 0.975 ± 0.458 ng/ml, p = 0.001) and control group (0.982 ± 0.060 ng/ml, p < 0.001), respectively. Receiver operating characteristic (ROC) analysis of apelin as a predictor of AF scored area under the curve (AUC) of 0.658. Apelin's concentration of 0.969 [ng/ml] had sensitivity = 0.966 and specificity = 0.467. Logistic regression based on manual feature selection showed that only apelin and NT-proBNP were independent predictors of AF. Logistic regression based on selection from bivariate analysis showed that only apelin was an independent predictor of AF. A logistic regression model using repeated stratified K-Fold cross-validation strategy scored an AUC of 0.725 ± 0.131. CONCLUSIONS: Our results suggest that apelin might be used to rule out AF in patients with high risk of stroke.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Frontiers in Cardiovascular Medicine

ISSN

2297-055X

e-ISSN

2297-055X

Svazek periodika

8

Číslo periodika v rámci svazku

October 2021

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

10

Strana od-do

742601

Kód UT WoS článku

000713254800001

EID výsledku v databázi Scopus

—